Biotech News

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

Tempest Therapeutics (TPST)Tempest TherapeuticsCompany update

Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companies BRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo

Related news

Tempest Therapeutics

In Vivo CAR-T Platform Tempest Therapeutics is developing targeted lentiviral approaches intended to generate CAR T cells directly inside patients. The strategy seeks to avoid patient-specific ex vivo manufacturing and broaden the use of engineered-cell therapy. TPST-4903 TPST-4903 is the lead in vivo CAR-T candidate from the licensed...

Recent company news

Stock data

Close
0.31 USD
Market cap
19.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States